Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s

Japanese Firm Notes Challenges In Developing IBD Biologics

 
• By Dean Rudge
  
Takeda Tokyo HQ
No EU, US, or Japan Phase I trials have started • Source: Ian Haydock/Scrip
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products